Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

NCT01683825
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir PET
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

NCT02266563
Conditions
Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
Interventions
Amyvid PET Scan, T807 PET scan
Drug
Lead sponsor
Samuel Gandy
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Completed Phase 4 Interventional Results available

Evaluation of Reader Training Processes

NCT02051790
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Conditions
Amyloidosis, Primary, Cardiomyopathy
Interventions
F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET
Radiation · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Completed Phase 4 Interventional Results available

The Feasibility of Florbetapir Quantitation

NCT01946243
Conditions
Alzheimers Disease
Interventions
Florbetapir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
florbetapir F 18 PET scan
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
75
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

NCT01834716
Conditions
Alzheimer's Disease Prevention
Interventions
Aerobic vs. Non-Aerobic exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 22 more
Conditions
Alzheimer's Disease (AD)
Interventions
[18F]T807
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Conditions
Progressive Cognitive Decline
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Postoperative Cognitive Dysfunction
Interventions
Florbetapir F 18 (18F-AV-45), no intervention
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Interventions
LY4560736, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more